7:00 am Morning Coffee & Registration
8:15 am Chairperson’s Opening Remarks
Illustrating Cutting-Edge Antibody-Drug Conjugates Revolutionizing the Oncology Field
8:30 am Outlining the Phase III Approval of ImmunoGen’s ELAHERE, Lessons Learned & Next Steps
Synopsis
- Exploring the rollercoaster journey of ImmunoGen’s Mirvetuximab Soravtansine, which targets folate receptor alpha
- Emphasizing the importance of designing a clinical trial to enrol the right patients and utilizing biomarker strategies
- Discussing the next steps for ImmunoGen following this ground-breaking approval
9:00 am Our History To Serve The Innovators: A Step Ahead Against The Challenges Of The Bioconjugates
Synopsis
- Exploring a sustainable business model
- Discussing expertise, technology and integration of services
- Examining capacity shortage challenges: what it means going forward?
9:30 am Discussing the Role Daiichi Sankyo & AstraZeneca’s ENHERTU Has Played in Developing & Expanding the Antibody-Drug Conjugate Field
Synopsis
- The approval of Daiichi Sankyo & AstraZeneca’s ENHERTU for HER2-low breast cancer has continued to make major waves throughout the ADC field
- Exploring the next steps in utilizing ADCs in breast cancer following this approval
- Discussing the unique features of TOPO1-inhibitor that make ENHERTU so effective
10:00 am Morning Refreshments & Speed Networking
Synopsis
This session is the ideal opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. Utilize this dedicated networking time for face-to-face interactions with many of the brightest minds working in the ADC field to form meaningful business relationships, and swap business cards using our app.
Discovery Chemistry
Chair: Thomas Nittoli, Senior Director, Regeneron
Cutting-Edge Conjugation Technologies Spearheading the Early Discovery ADC Field
Download the Full Event Guide for full details
11.00 Novel Technologies for Expanding ADC Therapeutic Index
Shalom Goldberg, Senior Principal Scientist, Johnson & Johnson
11:30 Highly Selective ADCs With OHPAS-able & PMT-able Camptothecins: Basics of OHPAS Linker
Tae Kyo Park, Chief Executive Officer, IntoCell
12:00 Development of Next-Generation ADCs Using Novel Expression Platforms & Precise Conjugation
Gang Yin, Vice President Protein Chemistry, Sutro Biopharma
12:30 Maximizing Payload Potential Through Linker and Bioconjugation Technologies
Johanna Midelet, Bioconjugation Manager, Abzena
1:00 pm Lunch & Learn with Sterling Pharma Solutions
Discovery Chemistry
Designing Your ADC to Minimize Off-Target Toxicities
Download the Full Event Guide for full details
2.00 Discovery of Novel Linker Payloads with Improved Efficacy & Therapeutic Index for Site-Specific ADCs
Krishna Bajjuri, Senior Director, Chemistry, Sutro Biopharma
2:30 Technological & Biochemical Innovations for Expanding the Therapeutics Index of ADCs
Christine Köhler, Head of Antibody Engineering, Veraxa Biotech
3:00 Towards Designing Ultra-Low Dose Precision Immunotherapeutics Without Toxicities
Jan Schnitzer, Founder, Director & Chief Executive Officer, PRISM
3:30 pm Technology Slam & Afternoon Networking Break
Synopsis
As you enjoy your afternoon refreshments, you will also have the chance to be face-to-face with the field’s most innovative and exciting technology providers. Join our dedicated technology slam to identify your next technology provider and progress your antibody-drug conjugate pipeline smoothly and efficiently.
Outlining Trailblazing Antibody-Drug Conjugate Clinical Candidates
4:30 pm Case Study: Exploring Novel Antibody-Drug Conjugates Storming Through the Clinic
Synopsis
- Following a record-breaking year for ADCs entering the clinic, this session will focus on some of the most exciting clinical candidates and positive Phase I data
- Discussing the key preclinical data indicative of future clinical success
- Outlining different clinical trial designs, with the disadvantages and advantages of each design
5:00 pm Innovative Chitooligosaccharide-Based Solubility Enhancer for Linker-Payloads: Improved Efficacy & New Life for Challenging Payloads
Synopsis
- Introduction to Chetosensar™ technology, a new chitooligosaccharide-based solubility enhancer that can be used with a wide range of linker-payload chemistries and conjugation methods
- Discussion of in vitro studies demonstrating increased efficacy and previously unattainable high DAR species
- Overview of how Chetosensar™ technology works with our CDMO services and ADCore™ intermediates to deliver rapid access to new linker-payloads
5:30 pm Precision Engineering for Enhanced Therapeutic Index: Designing Antibody-Drug Conjugates (ADCs) for Broadened Efficacy & Safety
Synopsis
- Discovery and development if a novel Tissue Factor ADC with potent efficacy and strong safety using a newly designed linker payload
- Exploration of linker-payload attributes that improve safety and widen the therapeutic index
- Exploring what is on the horizon for next-generation ADCs? ADC2 modality combines synergistic payload mechanisms for targeted synthetic lethality
6:30 pm Poster Session & Drinks Reception
Synopsis
Join your peers in the ADC field by presenting your work in our dedicated ADC poster session. This is the perfect opportunity to discuss, debate, and display your work in the field, while enjoying a drink of your choice at our dedicated drinks reception.
